|
VRK1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.04259999522682E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.38780000508754E-08 |
| Normal-vs-Stage2 |
1.36230005054472E-09 |
| Normal-vs-Stage3 |
1.543499994483E-08 |
| Normal-vs-Stage4 |
2.59720001061226E-09 |
| Stage1-vs-Stage2 |
2.320000E-02 |
| Stage1-vs-Stage3 |
3.137200E-01 |
| Stage1-vs-Stage4 |
6.334500E-02 |
| Stage2-vs-Stage3 |
1.346610E-01 |
| Stage2-vs-Stage4 |
6.824600E-01 |
| Stage3-vs-Stage4 |
2.806400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.00669999506076E-08 |
| Normal-vs-AfricanAmerican |
2.846000E-04 |
| Normal-vs-Asian |
1.22260000001706E-06 |
| Caucasian-vs-AfricanAmerican |
3.421600E-01 |
| Caucasian-vs-Asian |
5.268400E-01 |
| AfricanAmerican-vs-Asian |
6.648400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.49279999051811E-09 |
| Normal-vs-Female |
1.7001000052197E-08 |
| Male-vs-Female |
5.042600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.11549999962202E-07 |
| Normal-vs-Age(41-60Yrs) |
7.4064999688872E-09 |
| Normal-vs-Age(61-80Yrs) |
2.15380002721588E-09 |
| Normal-vs-Age(81-100Yrs) |
7.397200E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.175640E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.822400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.825600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.311800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.597200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.672600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.515000E-01 |
| Classical-VS-Follicular |
1.66649999999713E-06 |
| Classical-VS-Other |
5.621000E-01 |
| Classical-VS-Normal |
5.02639999955257E-07 |
| Tall-VS-Follicular |
4.204000E-02 |
| Tall-VS-Other |
8.163400E-01 |
| Tall-VS-Normal |
3.23049999995106E-06 |
| Follicular-VS-Other |
3.968400E-01 |
| Follicular-VS-Normal |
8.61819504649475E-11 |
| Other-VS-Normal |
1.927730E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.87439996857108E-09 |
| Normal-vs-N1 |
2.68800000036151E-08 |
| N0-vs-N1 |
9.289800E-01 |
|
|
